EPISODE · Nov 21, 2025 · 14 MIN
MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval
from MPR Weekly Dose
Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo approved for HER2-mutant NSCLC.
Embed this episode
Ready to play
MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval
0:00
14:50
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 14 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on November 21, 2025.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!